TaiDoc (4736) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 泰博

TaiDoc (4736) reported revenue of NT$439.9 million for Oct 2026, +53.9% year on year and +10.4% from the previous month. Revenue for Jan–Oct 2026 was NT$3.73 billion (+7.9% year on year).

Year-on-year revenue growth: 3 months in a row. →

In Oct 2026, it ranked No. 20 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$394.9 million24/10Nov 2024 NT$388.7 millionDec 2024 NT$383.6 millionJan 2025 NT$367.4 millionFeb 2025 NT$310.7 million25/02Mar 2025 NT$298.7 millionApr 2025 NT$392.5 millionMay 2025 NT$375.7 millionJun 2025 NT$352.8 million25/06Jul 2025 NT$427.6 millionAug 2025 NT$278.4 millionSep 2025 NT$372.1 millionOct 2025 NT$285.8 million25/10Nov 2025 NT$334.8 millionDec 2025 NT$407.7 millionJan 2026 NT$368.2 millionFeb 2026 NT$262.1 million26/02Mar 2026 NT$444.1 millionApr 2026 NT$368.2 millionMay 2026 NT$319.2 millionJun 2026 NT$360.2 million26/06Jul 2026 NT$376.6 millionAug 2026 NT$397.2 millionSep 2026 NT$398.4 millionOct 2026 NT$439.9 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$439.9 million+53.9%+10.4%
Sep 2026NT$398.4 million+7.1%+0.3%
Aug 2026NT$397.2 million+42.7%+5.5%
Jul 2026NT$376.6 million-11.9%+4.6%
Jun 2026NT$360.2 million+2.1%+12.8%
May 2026NT$319.2 million-15.0%-13.3%
Apr 2026NT$368.2 million-6.2%-17.1%
Mar 2026NT$444.1 million+48.7%+69.4%
Feb 2026NT$262.1 million-15.6%-28.8%
Jan 2026NT$368.2 million+0.2%-9.7%
Dec 2025NT$407.7 million+6.3%+21.8%
Nov 2025NT$334.8 million-13.9%+17.2%
Oct 2025NT$285.8 million-27.6%-23.2%
Sep 2025NT$372.1 million-15.8%+33.7%
Aug 2025NT$278.4 million-26.0%-34.9%
Jul 2025NT$427.6 million+3.2%+21.2%
Jun 2025NT$352.8 million-9.8%-6.1%
May 2025NT$375.7 million-1.1%-4.3%
Apr 2025NT$392.5 million+0.0%+31.4%
Mar 2025NT$298.7 million-19.8%-3.9%
Feb 2025NT$310.7 million+8.6%-15.4%
Jan 2025NT$367.4 million-12.5%-4.2%
Dec 2024NT$383.6 million+14.4%-1.3%
Nov 2024NT$388.7 million+9.4%-1.5%
Oct 2024NT$394.9 million+1.8%-10.6%

Jan–Oct 2026 cumulative: NT$3.73 billion (+7.9% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: TaiDoc vs PEC / TaiDoc vs Lotus Pharm / TaiDoc vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

因多參數量測儀及試片出貨量增加

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16